Navigation Links
Sigma-Aldrich Offers Customizable Synthetic Extracellular Matrix for Stem Cell Research
Date:8/13/2009

ST. LOUIS, Mo., Aug. 13 /PRNewswire-FirstCall/ -- Sigma-Aldrich(R) (Nasdaq: SIAL) today announced an agreement with Glycosan BioSystems for the sale of HyStem(TM), a fully customizable synthetic extracellular matrix (ECM) for stem cell research. HyStem offers researchers flexibility to tailor microenvironments for their cultured cells that mimic natural in vivo conditions, optimizing stem cell proliferation and differentiation. HyStem was developed by Glycosan BioSystems and will be sold by Sigma-Aldrich under a non-exclusive distribution agreement (http://www.sigma.com/hystem).

The HyStem platform consists of hydrogel cell culture scaffolds that provide a complex, three dimensional environment in which cells are able to proliferate, much as they would in vivo. Composed of hyaluronic acid and denatured collagen, HyStem's synthetic matrix offers greater control of the cellular environment than ambiguous extracted ECM alternatives. Customizable microenvironments enable researchers to optimize the growth conditions for each distinct cell type in a multicellular organism.

"Our HyStem ECMs provide a new level of control over the stem cell growth environment than what was previously available to the research community. We believe this ECM platform will greatly aid researchers in advancing global stem cell research," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech business unit. "Sigma-Aldrich provides more than 1,100 unique, highly-focused products to support every aspect of the stem cell research workflow, from isolation, characterization, expansion, differentiation and functional profiling to in vitro/in vivo tracking. The addition of HyStem products to our portfolio enhances our position as a leading source of technologies that support the growing stem cell market."

The HyStem platform includes three unique options: HyStem, HyStem-C and HyStem-HP. HyStem is available to researchers who want to customize their own attachment factors, ECM proteins and peptides, and who require an animal-component-free system with a minimal number of cell attachment sites. Researchers requiring a large number of generalized cell attachment sites for their stem cell cultures will benefit from HyStem-C. HyStem-HP is available for scientists planning to incorporate and gradually release growth factors into the stem cell environment. All options are consistently formulated and well characterized for both in vivo and in vitro experimentation.

Sigma-Aldrich's regenerative medicine experts continue to identify and develop promising technologies that support this rapidly-evolving research area. HyStem expands the Sigma-Aldrich portfolio of advanced stem cell research technologies, available through the company's web portal at http://www.sigma-aldrich.com/stemcell.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.

Sigma-Aldrich is a registered trademark of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. HyStem, HyStem-C and HyStem-HP are trademarks of Glycosan BioSystems, Inc.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sigma-Aldrich (Nasdaq: SIAL) Reports 6% Increase In First Quarter 2009 Diluted EPS to $0.68. All Research Units Achieve Organic Sales Growth. Full Year 2009 Guidance Reaffirmed; Diluted EPS Expected to Exceed Reported EPS for 2008 of $2.65.
2. Sigma-Aldrich Announces Appointment of Michael Kanan as Vice President and Corporate Controller
3. Sigma-Aldrich Enters Distribution Agreement With AlphaGenix, Inc.
4. Sigma-Aldrich and Atlas Antibodies Announce the Release of 2,000 New, Highly-Validated Prestige Antibodies
5. Sigma-Aldrich Shareholders Elect Directors and Ratify Auditor; Directors Declare Quarterly Dividend
6. Sigma-Aldrich Amends Credit Facility and Expands Commercial Paper Program
7. Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo
8. Sigma-Aldrich Announces mirPremier(TM) microRNA Isolation Kit for miRNA Purification
9. Living Peacefully in a Big City: Natural Health Practitioner Offers Advice on Maintaining Sanity, Health and Happiness
10. Institute Chastises Congress on Health Care Reforms, Offers Five-Point Program for Reducing Health Care Costs by 50%
11. Gene Therapy Offers Hope Against Inherited Blindness
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 28, 2017 , ... Columbus OH. Dr. Justin Harper, Founder of Juvly Aesthetics ... in the country to sit on the 2017 National Advisory Board for Allergan’s Facial ... Dr. Harper helped propel the clinic from a small start-up to number 78 in ...
(Date:3/28/2017)... ... March 28, 2017 , ... AutismOne announced the Board ... of Integrative Medicine and available for application on Saturday, May 27, 2017, following ... in Colorado Springs. , Ed Arranga, president of AutismOne, stated: "Many of the ...
(Date:3/28/2017)... Square, PA (PRWEB) , ... March 28, 2017 , ... ... online and across a variety of business channels. , While many results are ... of any public relations program. , When it comes to measurement, firms should ...
(Date:3/28/2017)... Perry, GA (PRWEB) , ... March 28, 2017 , ... ... headquarters to Marshallville, Georgia, in early March. , The seed processing plant opened in ... the location since 2016. The new office allows opportunity for transition of Patten Seed ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common and ... Advanced Dermatology has a lot to offer to the discussion of dealing with ... news is that there are many home remedies that can help remove the oily shine ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... Md. , March 27, 2017  ImMAGE Biotherapeutics ... its immunotherapy successfully passed early toxicology and efficacy studies. ... system to target a specific protein, MAGE A, in ... negative breast cancer. After 4 weeks ... able to show very little toxicity in a full ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
(Date:3/27/2017)... CHICAGO , March 27, 2017  A ... Educators (AADE) found that Medicare,s Competitive Bidding Program (CBP) ... diabetes testing supplies. The lack of choice forces beneficiaries ... can have dire health consequences. AADE,s ... reports by AADE and others pointing out the inherent ...
Breaking Medicine Technology: